Smart Buildings About the Author
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Modern Healthcare
http://www.modernhealthcare.com/article/20160319/MAGAZINE/303199964?utm_source=modernhealthcare&utm_medium =email&utm_content=20160319-MAGAZINE-303199964&utm_campaign=financedaily Modern Healthcare Why venture capital firms are pouring money into health insurance By Bob Herman | March 19, 2016 Entrepreneur Vivek Garipalli has a dim view of the way health insurance companies treat providers and patients. Patients develop trust with doctors and hospitals, and he thought insurers should be the “glue” between them instead of creating friction. So Garipalli persuaded a couple of venture funds to pump $135 million into his own bid to build an insurer he describes as a technology-based clinical company, rather than “an actuarial engine” like the big legacy players. His company, Clover Health, sells only Medicare Advantage plans and has enrolled 16,000 members as of this month. It differs from UnitedHealth Group and other giants, Garipalli said, in the way it uses real-time patient data to connect seniors to the care they need. The plans also provide free primary-care visits, and notably, don't charge extra for seeing out-of-network providers. “The really large companies, like an Aetna or a United, they're really insurance companies at their core,” Garipalli said. “They spend a lot of money on technology, but we all know there's a big difference between spending a lot of money on technology and being a technology company.” Venture capitalists and entrepreneurs have been investing and building new health insurance and related companies at a torrid pace—which may seem odd, because the industry is highly regulated and has relatively low profit margins. -
Capital International Fund
Capital International Fund Audited Annual Report 2020 For the year ended 31 December 2020 Société d’Investissement à Capital Variable organised under the laws of the Grand Duchy of Luxembourg R.C.S. Luxembourg B 8833 1RVXEVFULSWLRQFDQEHDFFHSWHGRQWKHEDVLVRIWKHÀQDQFLDOUHSRUWV6XEVFULSWLRQVDUHRQO\YDOLGLIWKH\DUHPDGHRQWKHEDVLVRIWKH prospectus accompanied by the latest annual report and the latest semi-annual report, if published thereafter. Capital International Fund Audited Annual Report for the year ended 31 December 2020 Contents Report of the Board of Directors of the Company to the shareholders .............. 2 Summary information ..................................................... 4 Results (unaudited) ....................................................... 17 Historical data ........................................................... 36 Portfolio breakdown ....................................................... 52 Schedule of investments ................................................... 76 Capital Group New Perspective Fund (LUX) ............................. 76 Capital Group Global Equity Fund (LUX) ................................ 88 Capital Group World Growth and Income (LUX) .......................... 94 Capital Group World Dividend Growers (LUX) ........................... 104 Capital Group New Economy Fund (LUX) ............................... 108 Capital Group New World Fund (LUX) .................................. 115 Capital Group Emerging Markets Growth Fund (LUX) ..................... 131 Capital Group Japan Equity Fund -
SATURN PARTNERS LIMITED PARTNERSHIP III a Delaware Limited Partnership
Fourth Amended and Restated Confidential Private Placement Memorandum SATURN PARTNERS LIMITED PARTNERSHIP III A Delaware Limited Partnership PRIVATE PLACEMENT OF LIMITED PARTNERSHIP INTERESTS A venture capital fund that will source and lead investments focusing primarily on software and information technology, with secondary focus on specialty energy, biotechnology and advanced materials. The fund may also invest in follow-on investments in certain Saturn Affiliate portfolio companies and special opportunities that are believed to have potential for significant growth. The purchase of a limited partnership interest in Saturn Partners Limited Partnership III involves a high degree of risk. See “RISK FACTORS” in this Memorandum. September 1, 2012 Name of Offeree: Memorandum No.: A/75186653.1 THIS FOURTH AMENDED AND RESTATED PRIVATE PLACEMENT MEMORANDUM (THIS “MEMORANDUM”) AMENDS AND RESTATES THE THIRD AMENDED AND RESTATED PRIVATE PLACEMENT MEMORANDUM DATED SEPTEMBER 1, 2011, THE SECOND AMENDED AND RESTATED PRIVATE PLACEMENT MEMORANDUM DATED DECEMBER 1, 2010, THE AMENDED AND RESTATED PRIVATE PLACEMENT MEMORANDUM DATED AUGUST 1, 2010 AND THE PRIVATE PLACEMENT MEMORANDUM DATED JUNE 1, 2010, AND HAS NOT BEEN FILED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR HAS SUCH COMMISSION OR ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY DETERMINED WHETHER IT IS ACCURATE OR COMPLETE, OR PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS MEMORANDUM DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO BUY, A SECURITY IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION IN SUCH JURISDICTION. -
DBJ Annual Report
CORE VALUES Professionalism Integrity VISION Accountability MISSION In 2020 the Development Bank of Jamaica, Innovation The Development Bank of Jamaica an inclusive, innovative, accountable, provides opportunities to all Jamaicans, customer-centric and strategy-focused employer to improve their quality of life through of choice in Jamaica; has facilitated the creation development financing, capacity of over 250,000 new jobs over the past seven years building, public-private partnership and while being a major contributor to the country’s privatisation solutions in keeping with economic growth and social transformation. Government policy. The Development Bank of Jamaica was established in April 2000, the outcome of a merger between two wholly owned Government of Jamaica institutions, the Agricultural Credit Bank of Jamaica Limited and the National Development Bank of Jamaica Limited. In September 2006, the operations of the National Investment Bank of Jamaica were merged with the DBJ. The Ministry of Finance and Planning has portfolio responsibility for the DBJ. BACKGROUND Table of Contents Board of Directors 4 Public-Private Partnerships & Privatisation 42 Management Team 5 42 Project Overviews 43 Privatisation Transactions in Progress Chairman & Managing Director’s Report 6 44 Public-Private Partnerships 6 DBJ Delivers! Transactions in Progress 9 DBJ’s 2014/15 Performance 44 Projects Being Assessed for 10 Capacity Development Development as PPPs 12 The DBJ Receives an Improved Credit 45 Other Developments in the Rating Programme 13 Corporate -
Healthcare Investments and Exits | Mid-Year Report 2020 6 Date
MIDANUAL-YEAR REPORT Healthcare 2020 Investments and Exits Biopharma | HealthTech | Dx/Tools | Device Follow @SVB_Financial Engage #SVBHealthcare MID-YEAR Table of Contents REPORT 2020 Page Page Page Page 3 5 24 35 Highlights Investments Exits 2020 Outlook HealthcareHealthcare Investments Investments and & Exits | Mid-Year Report 2020 2 Healthcare Investments: Mid-Year 2020 Venture fundraising in healthcare soared to $10.4B in the first half of 2020, nearly Silicon Valley Bank Market Stats* matching 2019’s full-year record. Mezzanine “Mezz” markups and great IPO performance have driven outsized returns, allowing investors to raise new funds, many of which were larger than their previous fund. Company investment also spiked. 1H 2020 produced the largest two-quarter investment 53% period ever for venture-backed healthcare companies. Biopharma and dx/tools saw increases in investment vs. 1H 2019, despite financial market turbulence and negative of all VC-backed US impacts to many companies due to COVID-19. healthcare companies that raised rounds in 1H 2020 Biopharma Series A was stable in the first half, while overall investment is on pace for worked with SVB. record dollars in 2020. We continued to see a significant number of large crossover-led mezzanine financings in Q1 and Q2 2020. This mezzanine activity exceeds 2019’s pace and is a strong, positive sign for continued IPO activity. of the $15B in venture funding HealthTech investments remained steady in 1H 2020 but showed an 18% increase in deals raised in the US in 1H 2020 was vs. 1H 2019, solidifying healthtech as the most prolific deal sector. Alternative care, which $1 0B by companies that work with SVB. -
The Handbook of Financing Growth
ffirs.qxd 2/15/05 12:30 PM Page iii The Handbook of Financing Growth Strategies and Capital Structure KENNETH H. MARKS LARRY E. ROBBINS GONZALO FERNÁNDEZ JOHN P. FUNKHOUSER John Wiley & Sons, Inc. ffirs.qxd 2/15/05 12:30 PM Page b ffirs.qxd 2/15/05 12:30 PM Page a Additional Praise For The Handbook of Financing Growth “The authors have compiled a practical guide addressing capital formation of emerging growth and middle-market companies. This handbook is a valuable resource for bankers, accountants, lawyers, and other advisers serving entrepreneurs.” Alfred R. Berkeley Former President, Nasdaq Stock Market “Not sleeping nights worrying about where the capital needed to finance your ambitious growth opportunities is going to come from? Well, here is your answer. This is an outstanding guide to the essential planning, analy- sis, and execution to get the job done successfully. Marks et al. have cre- ated a valuable addition to the literature by laying out the process and providing practical real-world examples. This book is destined to find its way onto the shelves of many businesspeople and should be a valuable ad- dition for students and faculty within the curricula of MBA programs. Read it! It just might save your company’s life.” Dr. William K. Harper President, Arthur D. Little School of Management (Retired) Director, Harper Brush Works and TxF Products “Full of good, realistic, practical advice on the art of raising money and on the unusual people who inhabit the American financial landscape. It is also full of information, gives appropriate warnings, and arises from a strong ethical sense. -
Venture Capital and the Finance of Innovation, Second Edition
This page intentionally left blank VENTURE CAPITAL & THE FINANCE OF INNOVATION This page intentionally left blank VENTURE CAPITAL & THE FINANCE OF INNOVATION SECOND EDITION ANDREW METRICK Yale School of Management AYAKO YASUDA Graduate School of Management, UC Davis John Wiley & Sons, Inc. EDITOR Lacey Vitetta PROJECT EDITOR Jennifer Manias SENIOR EDITORIAL ASSISTANT Emily McGee MARKETING MANAGER Diane Mars DESIGNER RDC Publishing Group Sdn Bhd PRODUCTION MANAGER Janis Soo SENIOR PRODUCTION EDITOR Joyce Poh This book was set in Times Roman by MPS Limited and printed and bound by Courier Westford. The cover was printed by Courier Westford. This book is printed on acid free paper. Copyright 2011, 2007 John Wiley & Sons, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as permitted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc. 222 Rosewood Drive, Danvers, MA 01923, website www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030-5774, (201)748-6011, fax (201)748-6008, website http://www.wiley.com/go/permissions. Evaluation copies are provided to qualified academics and professionals for review purposes only, for use in their courses during the next academic year. These copies are licensed and may not be sold or transferred to a third party. -
The View Beyond Venture Capital
BUILDING A BUSINESS The view beyond venture capital Dennis Ford & Barbara Nelsen Fundraising is an integral part of almost every young biotech’s business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital. re you a researcher looking to start a Why and how did the funding landscape During the downturns, it quickly became Anew venture around a discovery made change? apparent that entrusting capital to third-party in your laboratory? Perhaps you have already The big changes in the life science investor alternative fund managers was no longer an raised some seed money from your friends landscape start with the venture capitalist effective strategy, and investors began to with- and family and are now seeking funds to sus- (VC). In the past, venture capital funds were draw capital. The main reason for the with- tain and expand your startup. In the past, the typically capitalized by large institutional drawal (especially from VCs in the early-stage next step on your road to commercialization investors that consisted of pensions, endow- life science space) was generally meager returns would doubtless have been to seek funding ments, foundations and large family offices across the asset class; despite the high risk and from angels and venture capital funds; today, with $100 million to $1 billion in capital long lockup periods that investors accepted in however, the environment for financing an under management. Traditionally, the major- return for a promise of premium performance, early-stage life science venture looks strik- ity of these institutions maintained a low-risk, VCs were often not returning any more capital ingly different from that familiar landscape low-return portfolio of stocks and bonds that than investors would have earned by making of past decades. -
Press Release David Stepp FINAL
Media Contact: Nicole Pack 650-475-3721 [email protected] FOR IMMEDIATE RELEASE Venrock Promotes David Stepp to Partner Palo Alto, Calif., July 31, 2013 – Venrock, a pioneering venture capital firm established in 1969 by the Rockefeller family, today announced the promotion of David Stepp to partner. In addition to helping shape firm strategy, Stepp oversees the firm’s operations and administration, including structuring of fundraisings, investor relations, human resources, and the finance and legal functions. Stepp advises portfolio companies and actively participates in the structuring and implementation of portfolio investments, exits and significant transactions. Stepp is also responsible for the regulatory and compliance functions of the firm and serves as chief compliance officer. “David Stepp has been a key contributor across all dimensions of our business over the last six years,” said Bryan Roberts, partner at Venrock. “David’s promotion is a recognition of his commitment to our firm, its limited partners and our entrepreneurs. He is a terrific colleague and richly deserves this recognition.” Stepp joined Venrock as general counsel in 2007 from Cooley LLP. At Cooley, his practice focused on the formation and representation of venture capital partnerships and the representation of emerging growth and small-cap public technology companies. Stepp earned his B.S. in Molecular and Cellular Biology from the University of Arizona and his J.D. from Harvard Law School. About Venrock Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Adify, Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Millennium Pharma, SlideShare and Tudou. -
Comment Letter on File No. S7-37-10
enrock Building Companies that Shape the Future January 23,2011 Via Electronic Mail Elizabeth M. Murphy Secretary Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-1090 [email protected] Re: Release No. IA-3111; File No 87-37-10, Exemptions/or Advisers to Venture Capital Funds, Private Fund Advisers With Less Than $150 Million in Assets Under Management, and Foreign Private Advisers (the Proposed Rules) Dear Ms. Murphy: On July 21,2010, President Obama signed into law the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) which, among other things, (i) amended the Investment Advisers Act of 1940 (Advisers Act) to eliminate the current exemption from registration for investment advisers with fewer than 15 clients and (ii) provided for a new exemption from registration for investment advisers solely to venture capital funds (VCF Exemption). The Dodd-Frank Act further required or authorized the Securities and Exchange Commission (the Commission) to adopt or revise certain rules applicable to investment advisers, including a rule defining a ''venture capital fund" (VCF). The Proposed Rules set forth this new definition. Venrock1 is pleased to have the opportunity to comment on the Proposed Rules, with a specific focus on the Commission's proposed definition ofa VCF for purposes ofthe new VCF Exemption. Once finalized, the Commission's definition ofa VCF will have a significant impact on the venture capital industry, not only defining which venture capital funds will continue to be exempted from the significant expense and time commitment required to comply with the reporting regime under the Advisers Act, but also for the first time setting forth a common definition ofa venture capital fund that is likely to be incorporated into future federal and state legislation entirely unrelated to the securities laws. -
Bryce Start-Up Space 2017
Start-Up Space Update on Investment in Commercial Space Ventures 2017 Formerly Tauri Group Space and Technology Contents Executive Summary . i Introduction . 1 Purpose and Background . 1 Methodology . 1 Overview of Start-Up Space Ventures. 4 Overview of Space Investors .......................6 Space Investment by the Numbers ................13 Seed Funding . 14 Venture Capital . 15 Private Equity . 17 Acquisition . 17 Public Offering . 17 Debt Financing . 18 Investment Across All Types . 18 Valuation . 19 Space Investors by the Numbers ..................20 Overall . 20 Angels . 23 Venture Capital Firms . 25 Private Equity Groups . 28 Corporations . 29 Banks and Other Financial Institutions . 31 Start-Up Space: What’s Next? . 32 Acknowledgements .............................34 3 Executive Summary he Start-Up Space series examines space investment in the 21st century and analyzes Tinvestment trends, focusing on investors in new companies that have acquired private financing. Space is continuing to attract increased attention in Silicon Valley and in investment communities world-wide . Space ventures now appeal to investors because new, lower-cost systems are envisioned to follow the path terrestrial tech has profitably traveled: dropping system costs and massively increasing user bases for new products, especially new data products . Large valuations and exits are demonstrating the potential for high returns . Start-Up Space reports on investment in start-up space ventures, defined as space companies that began as angel- and venture capital-backed start-ups . The report tracks seed, venture, and private equity investment in start-up space ventures as they grow and mature, over the period 2000 through 2016. The report includes debt financing for these companies where applicable to provide a complete picture of the capital available to them and also highlights start-up space venture merger and acquisition (M&A) activity . -
Sherrie Quinn
Sherrie Quinn Associate Corporate and M&A, Financing and capital markets Primary practice Corporate and M&A, Financing and capital markets 27/09/2021 Sherrie Quinn | Freshfields Bruckhaus Deringer About Sherrie Quinn <p style="margin: 0in; margin-bottom: .0001pt;">Sherrie is a corporate associate in Silicon Valley. She represents leading technology and life sciences companies in the software/SaaS, hardware, digital media, biotech, and internet industries. Her representation of companies spans the corporate lifecycle, with a focus on mergers, acquisitions, public offerings, divestitures, financings, and other strategic transactions.</p> <p style="margin: 0in; margin-bottom: .0001pt;"> </p> <p style="margin: 0in; margin-bottom: .0001pt;">Prior to joining Freshfields, Sherrie was an associate in the San Francisco office of Goodwin Procter, where she represented iconic venture capital firms and<span style="color: red;"> </span>emerging and later-stage companies in the software, technology, and life sciences industries throughout their corporate life cycle, including pre-incorporation planning, general corporate representation and counseling, venture capital financings, and mergers and acquisitions.</p> Recent work <h3>Capital Markets</h3> <ul> <li><a href="http://news.freshfields.com/profiles/Global/r/6105/freshfields_serves_as_issuer_s_counsel_to_zymergen_on_its">Zymergen on its Initial Public Offering as a public benefit corporation valued over $4bn</a></li> <li><a href="http://news.freshfields.com/en/Global/r/5938/freshfields_advises_goldman_sachs___co__llc_in_connection">Goldman